NM 108

Drug Profile

NM 108

Alternative Names: NM108; NM108-MiDROPS™

Latest Information Update: 17 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuMedics
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Collagenase inhibitors; Inflammation mediator inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Diabetic retinopathy; Eye disorders; Uveitis

Most Recent Events

  • 12 Jun 2015 NeuMedics announces intention to file an IND to US FDA by 2017 (NeuMedics website, June 2015)
  • 12 Jun 2015 NeuMedics plans phase IIa and III trials for Diabetic macular oedema in USA (NeuMedics pipeline, June 2015)
  • 04 May 2015 Preclinical trials in Diabetic Retinopathy, Diabetic macular oedema, Uveitis and Eye disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top